1. Preventing acute asthmatic symptoms by targeting a neuronal mechanism involving carotid body lysophosphatidic acid receptors.
- Author
-
Jendzjowsky NG, Roy A, Barioni NO, Kelly MM, Green FHY, Wyatt CN, Pye RL, Tenorio-Lopes L, and Wilson RJA
- Subjects
- Acrylamides pharmacology, Animals, Asthma etiology, Asthma metabolism, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Disease Models, Animal, Drug Evaluation, Preclinical, Lysophospholipids pharmacology, Male, Rats, Inbred BN, Rats, Sprague-Dawley, Receptors, Lysophosphatidic Acid antagonists & inhibitors, TRPV Cation Channels antagonists & inhibitors, Acrylamides therapeutic use, Asthma prevention & control, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Carotid Body metabolism, Lysophospholipids therapeutic use, Receptors, Lysophosphatidic Acid metabolism, TRPV Cation Channels metabolism
- Abstract
Asthma accounts for 380,000 deaths a year. Carotid body denervation has been shown to have a profound effect on airway hyper-responsiveness in animal models but a mechanistic explanation is lacking. Here we demonstrate, using a rat model of asthma (OVA-sensitized), that carotid body activation during airborne allergic provocation is caused by systemic release of lysophosphatidic acid (LPA). Carotid body activation by LPA involves TRPV1 and LPA-specific receptors, and induces parasympathetic (vagal) activity. We demonstrate that this activation is sufficient to cause acute bronchoconstriction. Moreover, we show that prophylactic administration of TRPV1 (AMG9810) and LPA (BrP-LPA) receptor antagonists prevents bradykinin-induced asthmatic bronchoconstriction and, if administered following allergen exposure, reduces the associated respiratory distress. Our discovery provides mechanistic insight into the critical roles of carotid body LPA receptors in allergen-induced respiratory distress and suggests alternate treatment options for asthma.
- Published
- 2018
- Full Text
- View/download PDF